Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 12:18:43 GMT 2025
by
admin
on
Wed Apr 02 12:18:43 GMT 2025
|
| Protein Type | BISPECIFIC ANTIBODY |
| Protein Sub Type | IGG4 |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
M8FA2JKW5P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2795115-07-8
Created by
admin on Wed Apr 02 12:18:43 GMT 2025 , Edited by admin on Wed Apr 02 12:18:43 GMT 2025
|
PRIMARY | |||
|
M8FA2JKW5P
Created by
admin on Wed Apr 02 12:18:43 GMT 2025 , Edited by admin on Wed Apr 02 12:18:43 GMT 2025
|
PRIMARY | |||
|
C178408
Created by
admin on Wed Apr 02 12:18:43 GMT 2025 , Edited by admin on Wed Apr 02 12:18:43 GMT 2025
|
PRIMARY | |||
|
12767
Created by
admin on Wed Apr 02 12:18:43 GMT 2025 , Edited by admin on Wed Apr 02 12:18:43 GMT 2025
|
PRIMARY | |||
|
300000026732
Created by
admin on Wed Apr 02 12:18:43 GMT 2025 , Edited by admin on Wed Apr 02 12:18:43 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 3_134 | 3_194 |
| 3_23 | 3_88 |
| 2_267 | 2_325 |
| 2_161 | 2_221 |
| 2_22 | 2_97 |
| 1_370 | 1_428 |
| 1_264 | 1_324 |
| 1_232 | 2_129 |
| 1_229 | 2_126 |
| 1_150 | 1_206 |
| 1_137 | 3_214 |
| 1_22 | 1_96 |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_300 |
| N | 2_197 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> ACTIVATOR |
Pre-clinical
|
||
|
|
TARGET->LIGAND |
Pre-clinical
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
JNJ-75348780 (CD22xCD3) is a humanized IgG4-PAA bispecific antibody that can act as a bridge between CD22 positive malignant B-cells and CD3 positive cytotoxic T lymphocytes (CTLs),
redirecting these immune effector cells and thereby promoting the lysis of malignant B-cells with a high degree of specificity
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|